Lantern Pharma Inc. - Common Stock (NQ:LTRN)

0.6668 -0.0062 (-0.92%)

Delayed Quote Updated: 4:00 PM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

3 Penny Stocks to Buy as the AI Sector Transforms Every Industry in 2023 ↗

May 19, 2023

These AI penny stocks could potentially offer potent long-term value at tremendously attractive prices at this time

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023 ↗

May 18, 2023

Via Benzinga

Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET

May 17, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma's Earnings: A Preview ↗

March 17, 2023

Via Benzinga

Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights

May 09, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET

May 02, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound

May 02, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284

April 13, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer

March 28, 2023

From Lantern Pharma Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 27, 2023

Via Benzinga

Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars

March 21, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights

March 20, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting

March 15, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET

March 13, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank

March 13, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors

March 09, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.

March 08, 2023

From Lantern Pharma

Via Business Wire

Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers

March 06, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials

March 02, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352

February 27, 2023

From Lantern Pharma Inc.

Via Business Wire

7 AI Penny Stocks That Could Skyrocket in 2023 ↗

February 21, 2023

AI penny stocks represent great potential and high returns, given the fact this technology is only beginning to pervade society.

Via InvestorPlace

Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates

February 15, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023

January 17, 2023

From Lantern Pharma Inc.

Via Business Wire

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma

January 05, 2023

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting

December 15, 2022

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)

December 13, 2022

From Lantern Pharma Inc.

Via Business Wire

BioMedNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) to Present at RHK Capital Disruptive Growth Conference

December 02, 2022

Via Investor Brand Network

Topics Artificial Intelligence

Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting

November 22, 2022

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights

November 07, 2022

From Lantern Pharma Inc.

Via Business Wire

Earnings Preview: Lantern Pharma ↗

November 04, 2022

Lantern Pharma (NASDAQ:LTRN) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Lantern Pharma...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.